Peculiarities of blood formation from bone marrow in secondary chronic inflammation on the background of mesenchymal stem cells

Abstract

The use of MSCs reduces the chronicity of inflammation due to greater activation of hematopoiesis, and, consequently, the entry of leukocytes into the blood and the focus in the initial stages of inflammation. The study of bone marrow hematopoiesis in the dynamics of secondary chronic inflammation shows that the use of MSCs reduces the chronicity of the process. This proves the possibility of using MSCs to prevent chronic inflammation.

Thus, inflammation on the background of the application of MSCs compared with the natural course of the process in the early stages of inflammation in the cell emigrates more leukocytes, compared with more distant terms, as they are less. In the early stages, there is more release of cells from the bone marrow into the blood, hematopoiesis is more significantly stimulated, and in the later stages, corresponding to the period of chronic inflammation - less activation of hematopoiesis.

This is probably because the increased migration of leukocytes into the site of inflammation in the early stages of the process provides a more effective fight against inflammation and, consequently, less likely to chronicle the process.

The use of MSCs leads to a decrease in the chronicity of inflammation due to greater activation of hematopoiesis, and, consequently, the entry of leukocytes into the blood and hearth in the initial stages of inflammation.

The results of our studies of bone marrow hematopoiesis in the dynamics of secondary chronic inflammation show that the use of MSCs reduces the chronicity of the process.

The prospect of further research is related to the improvement of pathogenetic therapy and the prevention of chronic inflammation. Further additional research should be conducted to study not only the local effect of MSCs on the course of inflammation but also the systemic administration of MSCs.